替格瑞洛的合成工艺改进

以2-丙硫基-4,6-二氯-5-氨基嘧啶(3)、2-[((3aR,4S,6R,6a S)-6-氨基-2,2-二甲基四氢-3a H-环戊基[d][1,3]二氧-4-基)氧]-1-乙醇L-酒石酸盐(4)为起始原料,经亲核取代、环合、与(1R,2S)-2-(3,4-二氟苯基)环丙胺D-扁桃酸盐(2)发生亲核取代、稀盐酸脱保护制得抗血小板药替格瑞洛,所得目标经1H NMR及MS确证,总收率为65%。     

替格瑞洛中间体的合成

以(3a S,4R,6S,6aR)-6-羟基-2,2-二甲基-四氢-3a H-环戊烷并[d][1,3]-二氧环戊烯-4-氨基甲酸苄酯为原料,经烯丙基取代、双键双羟基化、Smith降解、脱保护基和成盐反应,合成了替格瑞洛中间体(3a S,4R,6S,6aR)-6-(2-羟基乙氧基)-2,2-二甲基-四氢-3a H-环戊烷并[d][1,3]-二氧环戊烯-4-氨基草酸盐,总收率56.0%,其结构经1H NMR,13C NMR和ESI-MS确证。     

d-生物素的不对称全合成研究(Ⅴ)

以二异丁基氢化铝使(3aS,6aR)-1,3-二苄基-四氢-4H-噻吩并[3,4-d]-咪唑-2,4(1H)-二酮(1)高立体选择性地还原成(3aS,4S,6aR)-1,3-二苄基-4-羟基-四氢-1H-噻吩并[3,4-d]-咪唑-2(3H)-酮(2),再经缩合,Witting烯化成(3aS,6aR)-1,3-二苄基-四氢-1H-噻吩并[3,4-d]咪唑-2(3)-酮-4-烯戊酸(4),后者经催化氢转移还原、脱苄即得d-生物素,以化合物1计算总产率为42%.     

3-((1R,3aS,3aS,10aR)-十氢-(1H,4H)-吡啶并[1,6]萘啶-1-基)丙-1-胺的合成

以廉价易得的苦参碱为起始原料,经过开环、酯化反应、水解等步骤,得到4-((3aS,3aS,10aR)-2-(叔丁氧基羰基)十氢-(1H,4H)-吡啶并[1,6]萘啶-1-基)丁酸(5)。5再经过Curtius重排反应,得到叔丁基(1R,3aS,3aS,10aR)-1-(3-(((苄氧基)羰基)氨基)丙基)八氢-(1H,4H)-吡啶并[1,6]萘啶-2(3H)-羧酸叔丁酯(6)。然后,6脱去Cbz基团得到(1R,3aS,3aS,10aR)-1-(3-氨基丙基)八氢-(1H,4H)-吡啶并[1,6]二氮杂萘-2(3H)-羧酸叔丁酯(7),最后,7脱去Boc基团成功得到苦参碱衍生物的重要中间体3-((1R,3aS,3aS,10aR)-十氢-(1H,4H)-吡啶并[1,6]萘啶-1-基)丙-1-胺(8),总收率28%。目标化合物和中间体的结构经¹H NMR, ¹³C NMR和HR-MS确证。      

一种新型噁唑烷酮类抗生素的合成

以2,4-二溴吡啶为原料,经Weinreb酰胺酰化、Noyori不对称氢转移反应、脱Boc保护基、环化、Suzuki偶联、磷酸单酯化及成盐共七步反应制得一种新型噁唑烷酮类抗生素【【(3R,3aS)-7-{6-［(S)3-甲基-2-噁唑烷酮-5-基］吡啶-3-基}-1-氧-1,3,3a,4-四氢苯并［b］噁唑［3,4-d］［1,4］噁嗪-3-基】甲基】磷酸单酯二钠盐,其结构经¹H NMR, ¹³C NMR和HR-MS（ESI）确征,总收率7%,纯度99.7%。     

手性毛细管气相色谱法拆分4-氯甲基-2,2-二甲基-1,3-二氧戊环对映异构体

手性化合物具有独特的生物活性,其在药物治疗中发挥着关键作用。为准确测定对映异构体中不同构型的纯度,建立手性化合物对映体分离方法十分关键。4-氯甲基-2,2-二甲基-1,3-二氧戊环是一种重要的手性医药中间体,本文建立了一种手性毛细管气相色谱拆分测定4-氯甲基-2,2-二甲基-1,3-二氧戊环对映异构体的方法。采用固定相为环糊精衍生物的色谱柱Rt-bDEXse进行分离,并以氢火焰离子化检测器进行检测。经过优化,得到最优色谱条件：线速度为70 cm/s;升温程序为初始柱温70℃保持1 min,以2.0℃/min的速率升温到150℃;溶样溶剂为甲醇。实验结果表明,在该条件下,(R)-4-氯甲基-2,2-二甲基-1,3-二氧戊环和(S)-4-氯甲基-2,2-二甲基-1,3-二氧戊环可在10 min内快速分离,两者的分离度远大于1.5,在0.5～50.0 mg/L的范围内线性关系良好,线性相关系数均大于0.998,(R)-和(S)-4-氯甲基-2,2-二甲基-1,3-二氧戊环的检出限分别为0.07和0.08 mg/L,定量限分别为0.22 mg/L和0.25 mg/L。以甲醇作为空白样品,进行0...     

d-生物素的不对称全合成研究(Ⅱ)

1,3－二苄基咪唑啉－2－酮－顺－4,5－二羟酸经脱水、单酯化,折分成分（4S,5R）－顺1,3－二苄基－5－甲氧基羧基－2－氧代咪唑啉－4－羧酸,再经还原环合,硫代成(3aS,6aR)-1,3－二苄基－四氢－4H－噻吩并[3,4-d)咪唑－2,4（1H)-二酮（7）,后者经格氏反应、脱水、还原、裂解环合一锅合成（3aR,8aS,8bS)－1,3－二苄基－2－氧代十氢咪唑[3,4-d]噻吩并[1,2-a]锍翁溴化物（11）,继而经缩合、开环、水解、脱羧、脱苄而得d－生物素（1）,总收率为14．5％。     

含吡啶基的L-酒石酸衍生物的合成

以L-酒石酸为原料,合成了一端是羧酸、另一端是吡啶基的手性配体(4R,5R)-2,2-二甲基-5-[(4-吡啶氨基)羰基]-1,3-二氧戊环-4-甲酸和两端都是吡啶基的手性配体(4R,5R)-2,2-二甲基-N,N'-(吡啶-4-基)-1,3-二氧戊环-4,5-二甲酰胺,其结构经1H NMR,IR和MS表征.     

合成SGLT2抑制剂埃格列净的新方法

以D-(+)-葡萄糖酸内酯为原料,经三甲硅基保护羟基后与5-溴-2-氯-4′-乙氧基二苯甲烷偶联制得(2S,3R,4S,5S,6R)-2-［4-氯-3-(4-乙氧苄基)苯基］-6-(羟甲基)-2-甲氧基四氢-2H-吡喃-3,4,5-三醇（2）; 2经羟基保护、氧化和羟醛缩合等5步反应制得(3S,4S,5R,6S)-3,4,5-三(苄氧基)-6-［4-氯-3-(4-乙氧苄基)苯基］-2-(羟甲基)-6-甲氧基四氢-2H-吡喃-2-甲醛（7）; 7经还原、脱苄同时关环制得埃格列净(1S,2S,3S,4R,5S)-5-［4-氯-3-(4-乙氧苄基)苯基］-1-(羟甲基)-6,8-二氧杂二环［3.2.1］辛烷-2,3,4-三醇,其结构经¹H NMR和LC-MS表征。     

N-苄基-3(S)-邻苯二甲酰亚胺基-4(S)-[4(S)-2,2-二甲基-1,3-二氧环戊-4-基]-2-氧吖丁啶的合成

以L-抗坏血酸(1)为原料,经3步反应制得(S)-缩异丙氧叉甘油醛(4).该手性醛与苄胺缩合制得相应的手性亚胺(5).甘氨酸经保护后制成酰氯,在有机碱作用下首先生成不稳定的烯酮(8),继与手性亚胺5迅速进行[2+2]环加成反应,合成标题化合物N-苄基-3(S)-邻苯二甲酰亚胺基-4(S)-[4(S)-2,2-二甲基-1,3-二氧环戊-4-基]-2-氧吖丁啶.由于环加成的面向立体选择性容易控制,由此所得产物的光学纯度和化学收率均较高     

Investigation of reactions of the organozinc reagents prepared from zinc and dialkyl dibromomalonates with the derivatives of 2-arylmethyleneindan-1,3-dione and 5-arylmethylene-2,2-dimethyl-1,3-dioxane-4,6-dione

Organozinc compounds prepared from dialkyl dibromomalonates and zinc react with 2-arylmethyl-eneindan-4,6-diones, 5-arylmethylene-2,2-dimethyl-1,3-dioxane-4,6-diones, as well as with 2-[4-(1,3-dioxoindan-2-ylidenemethyl)phenyl]methyleneindan-1,3-dione and 5-[4-(2,2-dimethyl-4,6-dioxo-1,3-dioxane-2-ylidenemethyl)phenyl]methylene-2,2-dimethyl-1,3-dioxane-4,6-diones to form dialkyl 3-aryl-1′3′-dioxaspiro(cyclopropane-2,2′-indan)-1,1-dicarboxylates, dimethyl 3-aryl-6,6-dimethyl-5,7-dioxa-4,8-dioxaspiro[2,5]octan-2,2-dicarboxylates, dialkyl 2-{4-[3,3-bis (alkoxycarbonyl)-1′,3′-dioxaspiro(cyclopropane-2,2′-indan)-1-yl]phenyl}-1′,3′-dioxaspiro[cyclopropane-2,2′-indan]-1,1-dicarboxylates, and dialkyl 2-{4-[2,2-bis(alkoxycarbonyl)-6,6′-dimethyl-4,8-dioxo-5,7-dioxaspiro[2,5]oct-1-yl]phenyl}-6,6-dimethyl-4,8-dioxo-5,7-dioxaspiro[2,5]octan-1,1-dicarboxylate respectively.     

新型N~6-哌嗪取代腺苷衍生物的合成及其抗肿瘤活性

以腺苷为母体,对其N6-位进行结构改造,首先经邻位双羟基保护,N6-位氯代,再在N6-位引入哌嗪环制得中间体2',3'-异丙叉-6-哌嗪嘌呤核苷(4);4与N-氯乙酰苯胺类似物(6a~6h)偶联后脱除邻位双羟基保护合成了8个新型的N6-哌嗪取代腺苷衍生物(8a~8h),其结构经1H NMR,13C NMR和HR-ESI-MS表征。采用MTT法研究了8a~8h对Hela肿瘤细胞的抑制活性。结果表明:大部分目标化合物对Hela肿瘤细胞具有较好的抑制活性,其中2-{4-[9-(3,4-二羟基-5-羟甲基-四氢呋喃-2-基)-9H-嘌呤-6-基]-哌嗪-1-基}-N-(3-氟苯基)-乙酰胺(8e)的活性最好,IC50为21.74μmol·L-1。     

Di-4(3H)-quinazolinon-2-yl Derivatives from the Diacid Chlorides of Pinic and sym-Homopinic Acids

The corresponding diamides have been synthesized by the interaction of the diacid chlorides of cis-2,2-dimethyl-3-carboxycyclobutaneacetic acid (pinic acid) and cis-2,2-dimethylcyclobutane-1,3-diacetic acid (sym-homopinic acid) with two equivalents of anthranilic acid. Treatment of the diamides with formamide gave 2,2-dimethyl-1-[4(3H)-quinazolinon-2-yl]methyl-3-[4(3H)-quinazolinon-2-yl]cyclobutane and 2,2-dimethyl-1,3-di[4(3H)-quinazolinon-2-ylmethyl]cyclobutane respectively.     

Synthesis, characterization, and structure of cyclopenta[c]thiophenes and their manganese complexes

1,3-Diaryl-4H-cyclopenta[c]thiophenes are efficiently prepared from 1,2-diaroylcyclopentadienes by use of Lawesson's reagent. eta5-Cyclopenta[c]thienyl complexes, [Mn(eta5-SC7H3-1,3-R2)(CO)3] (R = Me, Ph), are prepared in high yield by ligand substitution reactions of [MnBr(CO)5] with [SnMe3(SC7H3-1,3-R2)]. Alternatively, thiation with P4S10/NaHCO3 converts [Mn{eta5-1,2-C5H3(COR)2)(CO)3] to [Mn(eta5-SC7H3-1,3-R2)(CO)3] (R = Ph, 4-tolyl, 4-MeOC6H4, benzo[2,3-b]thienyl). The molecular structures of complexes with R = Me, Ph show planar eta5-cyclopenta[c]thienyl ligands, with the manganese atom slightly displaced away from the ring-fusion bond.     

New heterocyclic structures. [1,2,5]Thiadiazolo[3′,4′:4,5]pyrimido-[2,1-b][1,3]thiazine and thiazolo[3,2a][1,2,5]thiadiazolo[3,4-d]pyrimidine

Derivatives of two new molecular structures, namely, 7,8-dihydro-6H,10H-[1,2,5]thiadiazolo[3′,4′:4,5]pyrimido[2,1-b][1,3]thiazin-10-one and 6,7-dihydro-9H-thiazolo[3,2-a][1,2,5]thiadiazolo[3,4-d][pyrimidin-9-one, and derivatives of N-substituted sulfamic acid, namely, (8-amino-3,4-dihydro-2H,6H-pyrimido[2,1-b][1,3]thiazin-6-on-7-yl)sulfamic acid and (7-amino-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidin-5-on-6-yl)sulfamic acid, were separated out as by-products in the reduction reaction of 8-amino-3,4-dihydro-7-nitroso-2H,6H-pyrimido[2,1- b][1,3]thiazin-6-one and 7-amino-2,3-dihydro-6-nitroso-5H-thiazolo[3,2-a]pyrimidin-5-one derivatives, respectively, with sodium hydrosulfite. A mechanism of reaction, which hypothesizes the action of sodium hydrosulfite in an asymmetic form, is proposed. The results of single-crystal X-ray investigation on 7,8-dihydro-6H,10H-[1,2,5]thiadiazolo[3′,4′:4,5]pyrimido[2,1-b][1,3]thiazin-10-one (R = 0.032 for 863 reflections) and (8-amino-3,4-dihydro-2H,6H-pyrimido[2,1-b]- [1,3]thiazin-6-on-7-yl)sulfamic acid, sodium salt (R = 0.028 for 3507 reflections) are reported.     

4-Aminofurazan-3-carboxylic Acid Iminoester in Reactions with N,O-Nucleophiles

Reactions of 4-aminofurazan-3-carboxylic acid iminoester with o-aminophenol and ethylenediamine give rise respectively to 4-(1,3-benzoxazol-2-yl)- and 1-(4,5-dihydro-1H-imidazol-2-yl)-1,2,5-oxadiazol-3-amines, with aminoethanol arises 2-[(Z)-1-amino-1-(4-amino-1,2,5-oxadiazol-3-yl)methylideneamino]-1-ethanol. Treating of 3-amino-4-(1H-benzo[d]imidazol-2-yl)-1,2,5-oxadiazole with triethyl orthoformate in acetic anhydride yielded benzo[4,5]imidazo[1,2-c][1,2,5]oxadiazolo[3,4-e]pyrimidine, and alkylation with haloalkanes furnished 3-amino-4-(1-R-benzo[d]imidazol-2-yl)-1,2,5-oxadiazoles.     

Comparison of various density functional methods for distinguishing stereoisomers based on computed (1)H or (13)C NMR chemical shifts using diastereomeric penam beta-lactams as a test set

Full (1)H and (13)C NMR chemical shift assignments were made for two sets of penam beta-lactams: namely, the diastereomeric (2S, 5S, 6S)-, (2S, 5R, 6R)-, (2S, 5S, 6R)-, and (2S, 5R, 6S)-methyl 6-(1,3-dioxoisoindolin-2-yl)-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylates (1-4) and (2S, 5R, 6R)-, (2S, 5S, 6R)-, and (2S, 5R, 6S)-6-(1,3-dioxoisoindolin-2-yl)-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acids (6-8). Each penam was then modeled as a family of conformers obtained from Monte Carlo searches using the AMBER* force field followed by IEFPCM/B3LYP/6-31G(d) geometry optimization of each conformer using chloroform solvation. (1)H and (13)C chemical shifts for each conformer were computed at the WP04, WC04, B3LYP, and PBE1 density functional levels as Boltzmann averages of IEFPCM/B3LYP/6-311 + G(2d,p) energies over each family. Comparisons between experimental and theoretical chemical shift data were made using the total absolute error (|Deltadelta| (T)) criterion. For the (1)H shift data, all methods were sufficiently accurate to identify the proper stereoisomers. Computed (13)C shifts were not always successful in identifying the correct stereoisomer, regardless of which DFT method was used. The relative ability of each theoretical approach to discriminate among stereoisomers on the basis of proton shifts was also evaluated.     

Synthesis of Some 3-Substituted 1,2-Dihydroindoles

The reaction of 4-oxo-2-(2-oxo-1,2-dihydroindol-3-ylidene)hydrazone-1,3-thiazin-6-methyl carboxylate 2 with hydrazine hydrate in methanol gave 4-oxo-2-(2-oxo-1,2-dihydroindol-3-ylidene)hydrazone-1,3-thiazin-6-carbonylhydrazine 3. Furthermore, the reaction of 3 with carbon disulfide and then hydrazine hydrate afforded 3-[6-(4-amino-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)-4-oxo-1,3-thiazin-2-yl] hydrazone-1,3-dihydroindol-2-one 5. the latest reacted with DMAD to give {6-hydroxy-3-[4-oxo-2-(2-oxo-1,2-dihydroindol-3-ylidene)hydrazone-1,3-thiazin-6yl]-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-7-ylidene}methoxycarbonylmethylene 6.     

A convergent approach to the marine natural product eleutherobin: synthesis of key intermediates and attempts to produce the basic skeleton

Synthesis of (1R,5R,6R)-2-(6-hydroxymethyl-5-isopropyl-2-methylcyclohex-2-enyl)-N- methoxy-N-methylacetamide 8 from R-(-)-phellandrene in six steps, and (3aR*,4S*,6R*,6aS*)- (6-hydroxymethyl-4-methoxy-2,2,6-trimethyltetrahydrofuro[3,4-d][1,3]dioxol- 4-yl)acetic acid methyl ester 17 from tetrabromoacetone and 2-methoxy-5-methylfuran in six steps, provided two key fragments which have been combined to produce intermediates for attempted construction of the basic skeleton of eleutherobin.     

Five new nortropane alkaloids and six new amino acids from the fruit of Morus alba LINNE growing in Turkey

Investigation of the constituents of the fruits of Morus alba LINNE (Moraceae) afforded five new nortropane alkaloids (1-5) along with nor-psi-tropine (6) and six new amino acids, morusimic acids A-F (7-12). The structures of the new compounds were determined to be 2alpha,3beta-dihydroxynortropane (1), 2beta,3beta-dihydroxynortropane (2), 2alpha,3beta,6exo-trihydroxynortropane (3), 2alpha,3beta,4alpha-rihydroxynortropane (4), 3beta,6exo-dihydroxynortropane (5), (3R)-3-hydroxy-12-[(1S,4S)-4-[(1S)-1-hydroxyethyl]-pyrrolidin-1-yll-dodecanoic acid-3-O-beta-D-glucopyranoside (7), (3R)-3-hydroxy-12-[(1S,4S)-4-[(1S)-1-hydroxyethyl]-pyrrolidin-1-yll-dodecanoic acid (8), (3R)-3-hydroxy-12-1(1R,4R,5S)-4-hydroxy-5-methyl-piperidin-1-yll-dodecanoic acid-3-O-beta-D-glucopyranoside (9), (3R)-3-hydroxy-12-[(1R,4R,5S)-4-hydroxy-5-methyl-piperidin-1-yll-dodecanoic acid (10), (3R)-3-hydroxy-12-[(1R,4R,5S)-4-hydroxy-5-hydroxymethyl-piperidin-1-yl]-dodecanoic acid-3-O-beta-D-glucopyranoside (11), and (3R)-3-hydroxy-12-[(1R,4S,5S)-4-hydroxy-5-methyl-piperidin-1-yl]-dodecanoic acid (12) on the basis of spectral and chemical data.